A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704.
Heestand G, Murphy J, Moughan J, Regine W, Luo J, Graber M, Kunz P, Fisher G, Guha C, Lin B, Mowat R, Gaur R, Buyyounouski M, Chen Y, Chang D, Koong A. A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704. Journal Of Clinical Oncology 2014, 32: 176-176. DOI: 10.1200/jco.2014.32.3_suppl.176.Peer-Reviewed Original ResearchDisease-free survivalMatrix metalloproteinase-7RTOG 9704MMP-7 serum levelsProximity ligation assaySerum samplesBaseline serum specimensBaseline serum samplesResected stage ILevels of CEAPancreatic cancer patientsPancreatic cancer therapyNovel biomarker panelNational Cancer InstituteGEM armImproved OSEligible patientsOS benefitAdjuvant therapyGemcitabine chemotherapySerum levelsCA 19Cancer patientsClinical endpointsPancreatic cancer